ReviewThe oncologist2014
Zollinger-Ellison syndrome: classical considerations and current controversies.
Review in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 80 citations in OpenAlex.
- Comparison study of gastrinomas between gastric and non-gastric origins.World journal of surgical oncology · 2015Trial
- Esophageal Perforation in Zollinger-Ellison Syndrome: A Scoping Review of Management and Outcomes.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Intestinal pH: a major driver of human gut microbiota composition and metabolism.Nature reviews. Gastroenterology & hepatology · 2025Review
- Enteroendocrine cells: the gatekeepers of microbiome-gut-brain communication.NPJ biofilms and microbiomes · 2025Review
- Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute.Endocrine oncology (Bristol, England) · 2025Article
- Etiologies of exocrine pancreatic insufficiency.Gastroenterology report · 2025Review
- Unravelling Peptic Ulcers: Comprehensive Insights into Etiology, Diagnosis, Screening Techniques, and Treatment.Current pharmaceutical design · 2025Review
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- Modern Management of Gastric Neuroendocrine Neoplasms.Current treatment options in oncology · 2024Review
- Early detection of multiple endocrine neoplasia type 1: A case report.World journal of gastroenterology · 2024Article
- Sporadic Zollinger-Ellison syndrome in a patient with isolated mesenteric gastrinoma.International journal of surgery case reports · 2024Article
- Typical Zollinger-Ellison syndrome-atypical location of gastrinoma and absence of hypergastrinemia: A case report and review of literature.World journal of clinical cases · 2023Article
- A Rare Case of Hepatic Gastrinoma.Cureus · 2023Article
- Single-cell transcriptomics uncovers EGFR signaling-mediated gastric progenitor cell differentiation in stomach homeostasis.Nature communications · 2023Article
- Esophageal Perforation Unveiling the Diagnosis of Zollinger-Ellison Syndrome.Journal of community hospital internal medicine perspectives · 2023Article
- Radiological Features of Zollinger-Ellison Syndrome: A Report of Two Cases.The Indian journal of radiology & imaging · 2022Article
- Nanofiber capsules for minimally invasive sampling of biological specimens from gastrointestinal tract.Acta biomaterialia · 2022Article
- Zollinger Ellison Syndrome Refractory to Medical Therapy in the Setting of Multiple Endocrine Neoplasia Type I.Cureus · 2022Article
- An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zollinger-Ellison syndrome (ZES) is an endocrinopathy characterized by gastrin-secreting tumors, responsible for causing the formation of multiple, refractory, and recurrent peptic ulcers in the distal duodenum and proximal jejunum. Two main variants have been described, sporadic and those found in association with parathyroid and pituitary tumors, a genetic disorder known as multiple endocrine neoplasia-1 (MEN-1). Biochemical serum evaluation for elevated gastrin, followed by radiological or nuclear localization of the primary lesion, is mandated for establishing diagnosis. The mainstays of treatment include management of hypersecretory state with medical suppression of gastric acid production and surgical resection of primary tumor for the prevention of malignant transformation and metastatic complications. Medical therapy with proton pump inhibitors has virtually eliminated the need for acid-reducing surgical procedures. Surgical approach to sporadic and MEN-1-associated ZES varies based on our understanding of the natural history of the condition and the probability of cure; however, resection to a negative microscopic margin is indicated in both cases. Postoperative surveillance involves measurement of gastrin level, followed by imaging if elevation is detected. Re-excision of recurrent or resection of metastatic disease is a subject of controversy; however, at the present time aggressive cytoreductive approach is favored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.